^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    NK cell stimulant

    Related drugs:
    1d
    Synergistic targeting of the ARID2-MYC axis by pomalidomide and panobinostat overcomes intrinsic IMiD resistance in multiple myeloma. (PubMed, Sci Rep)
    This finding highlights the functional relevance of IMiD's inherent polypharmacology in circumventing primary resistance mechanisms at the cellular level. Together, our results identify the ARID2-containing PBAF complex as a critical vulnerability in resistant myeloma cells and provide a mechanistic rationale for designing combination strategies that co-target this complex, with the potential to enhance therapeutic efficacy by overcoming drug resistance.
    Journal
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • ARID2 (AT-Rich Interaction Domain 2) • IRF4 (Interferon regulatory factor 4)
    |
    pomalidomide • Farydak (panobinostat)
    3d
    Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances (clinicaltrials.gov)
    P1/2, N=30, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=80 --> 30
    Enrollment closed • Enrollment change
    |
    cyclophosphamide • fludarabine IV • CAR.70/IL15-transduced CB-NK cells
    5d
    Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma (clinicaltrials.gov)
    P1, N=10, Recruiting, Dana-Farber Cancer Institute | Trial completion date: May 2030 --> Jul 2031 | Trial primary completion date: Dec 2025 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    CIML NK
    6d
    A Phase I Clinical Study Evaluating the Safety and Tolerability of CEL001 Injection in the Treatment of Advanced Solid Tumors (ChiCTR2600116105)
    P1, N=10, Recruiting, Cancer Hospital Chinese Academy of Medical Sciences; Guangzhou Celling Biological Technology Co., Ltd.
    New P1 trial
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    BRAF V600E • TMB-H • MSI-H/dMMR • BRAF V600
    6d
    A Multicenter Phase I Clinical Study of CD19-Targeted CAR-NK Cell Therapy for Moderate to Severe Active Systemic Lupus Erythematosus in China. (ChiCTR2600116668)
    P1, N=36, Not yet recruiting, Peking Union Medical College Hospital; Ruitherapeutics Co., LTD
    New P1 trial
    |
    MET positive
    |
    KN5501
    10d
    Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer (clinicaltrials.gov)
    P1, N=10, Completed, Zhejiang Provincial People's Hospital | Trial completion date: Sep 2025 --> Dec 2025
    Trial completion date
    |
    CLDN18 (Claudin 18)
    |
    cyclophosphamide • fludarabine IV
    11d
    A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD) (clinicaltrials.gov)
    P1, N=15, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Feb 2027 --> Jan 2026 | Trial primary completion date: Feb 2027 --> Jan 2026
    Trial completion • Trial completion date • Trial primary completion date • Minimal residual disease
    |
    Erbitux (cetuximab) • cyclophosphamide • fludarabine IV
    15d
    KN5501 Cell Injection for Refractory SLE(CLEAR) (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Ruitherapeutics Co., LTD
    New P1 trial
    |
    KN5501
    17d
    Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma (clinicaltrials.gov)
    P1, N=62, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2028 --> Jan 2029 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    pomalidomide
    28d
    CALiPSO-1: A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Century Therapeutics, Inc. | Recruiting --> Active, not recruiting | N=48 --> 6
    Enrollment closed • Enrollment change
    |
    CNTY-101
    1m
    NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, The First Affiliated Hospital of Guangzhou Medical University
    New P1 trial
    |
    EGFR L858R
    1m
    A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation (clinicaltrials.gov)
    P1, N=50, Recruiting, Dana-Farber Cancer Institute | Active, not recruiting --> Recruiting | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    IL2 (Interleukin 2)
    |
    cyclophosphamide • fludarabine IV • CIML NK